Dihexa in vitro research shows 7-9 orders of magnitude greater

Dihexa dose response research reveals cognitive effects scale with 0.5–2mg/kg

Dihexa long term studies remain sparse — most human trials

Dihexa safety studies show low acute toxicity in rodents with

Dihexa pharmacology studies reveal BDNF-mimetic properties that enhance synaptic plasticity

Dihexa comparative studies reveal superior BDNF elevation versus nootropic alternatives,

Dihexa activates HGF/Met signaling to induce dendritic spine formation and

Cerebrolysin study trials show consistent neuroprotective effects in stroke and

Cerebrolysin animal research shows significant neuroprotective effects through BDNF upregulation,

Cerebrolysin demonstrates neuroprotective effects across stroke, TBI, and Alzheimer’s research.

Cerebrolysin in vitro research demonstrates neuroprotection through BDNF upregulation, oxidative

Cerebrolysin dose response research shows optimal cognitive effects at 30–50ml

Cerebrolysin long term studies show sustained cognitive benefits over 6–12

Cerebrolysin safety studies reveal well-documented tolerability across 15+ randomized trials

DSIP study outcomes reveal mixed results across sleep, stress, and

Cerebrolysin comparative studies show neuroprotective effects in stroke and TBI

Top DSIP studies reveal sleep regulation mechanisms, neuroprotective effects, and

Thymosin alpha-1 animal research reveals immune-modulating mechanisms through T-cell differentiation

Cerebrolysin mechanism studies reveal multimodal neuroprotection through neurotrophic activity, synaptic

Thymosin alpha-1 long term studies reveal sustained immune modulation across

Thymosin alpha-1 safety studies show exceptional tolerability across 3,000+ patients